3D QSAR STUDIES ON PYRROLOPYRIMIDINES AS SELECTIVE P-GLYCOPROTEIN ANTAGONIST
Keywords:
P-glycoprotein, MDR, 3D-QSAR, Pharmacophore hypothesis, Regression coefficient, Squared predictive correlation coefficientAbstract
Objective: The present study is wrought to design the 3D QSAR models on pyrrolopyrimidines as p-glycoprotein inhibitors for the treatment of a wide variety of diseases.
Methods: A dataset comprising of 33 pyrrolopyrimidine derivatives have been divided into training set and test set. A three dimensional pharmacophore hypotheses were built from training set (24 compounds) using hydrogen bond acceptor, hydrophobic and aromatic features.
Results: The proposed model possesses high value of regression coefficient (0.9334) and was validated by using test set predictions. The squared predictive correlation coefficient of 0.985 was observed between experimental and predicted activity values of test set molecules.
Conclusion: The nature of fitness and the distance between pharmacophoric features explain the inhibitory activity of pyrollopyrimidines. The proposed pharmacophoric models possess as potential for the design of novel p-glycoprotein inhibitors.
Downloads
References
Maestro, Version 8.5, SchrÖdinger, LLC, NY2008. Chen X, Mao S. Titanium dioxide nanomaterials:synthesis, properties, modifications, and applications. J Chem Rev 2007;107:2891-959.
Colabufo NA, Berardi F, Perrone R, Rapposelli S, Digiacomo M, Vanni M, Balsamo A. 2-[(3-Methoxyphenylethyl)phenoxy]-Based ABCB1 Inhibitors:Effect of Different Basic Side-Chains on Their Biological Properties. J Med Chem 2008;5:7602-13.
Bisi A, Gobbi S, Rampa A, Belluti F, Piazzi L, Valenti P, Gyemant N, Molnas J. New Potent P-Glycoprotein Inhibitors Carrying Polycyclic Scaffold. J Med Chem 2006;49:3049-51.
Cordoncardo C, Obrien JP, Casals D, Grauert LR, Biedler JL, Melamed MR,. Bertino JR. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. J Proc Natl Acad Sci 1989;86:695-8.
Penzotti JE, Lamb ML, Evensen E, Grootenhuis EDJ. A Computational Ensemble Pharmacophore Model for Identifying Substrates of P-Glycoprotein. J Med Chem 2002;45:9.
Kuhnle M, Egger M, Muller C, Mahringer A, Bernhardt G, Fricker G,, Burkhard K, Buschauer A. Potent and Selective Inhibitors of Breast Cancer Resistance Protein (ABCG2) Derived from the p-Glycoprotein (ABCB1) Modulator Tariquidar. J Med Chem 2009;52:1190-7.
Leonessa F, Kim JH, Ghiorghis A, Kulawiec RJ, Hammer C, Talebian A, Clarke R. C-7 Analogues of Progesterone as Potent Inhibitors of the P-Glycoprotein Efflux Pump. J Med Chem 2002;45:390-8.
Schwab D, Fischer F, Tabatabaei A, Poli S, Jorg. Comparison of in Vitro P-Glycoprotein Screening Assays:Recommendations for Their Use in Drug Discovery. J Med Chem 2003;46:1716-25.
Colabufo NA, Berardi F, Cantore M, Contino M, Inglese C, Niso M, Perrone M. Perspectives of P-Glycoprotein Modulating Agents in Oncology and Neurodegenerative Diseases:Pharmaceutical, Biological, and Diagnostic Potentials. J Med Chem 2004 47:1816-25.
Tarasova NI, Seth R, Tarasov SG, Christine TK, Hrycyna A, Gottesman MM, Christopher J. Transmembrane Inhibitors of P-Glycoprotein an ABC Transporter. J Med Chem 2005;48:3768-75.
Leonessa F, Kim JH, Ghiorghis A, Robert J, Hammer KC, Talebian A, Clarke R. C-7 Analogues of Progesterone as Potent Inhibitors of the P-Glycoprotein Efflux Pump. J Med Chem 2002;45:390-8.
Pajeva IK, Michael Wiese. Pharmacophore Model of Drugs Involved in P-Glycoprotein Multidrug Resistance:Explanation of Structural Variety (Hypothesis). J Med Chem 2002;45:5671-86.
Asperen V, Mayer J, Tellingen UV, Beijnen JH. The functional role of P-glycoprotein in the blood-brain barrier. J Pharm Sci 1997;86:881-4.
Fellner S, Bauer B, Miller DS, Schaffrik M, Frankhanel M, Sprub T, Berhardt G, Graeff C, Farber L, Gschaidmeier H, Buschauer A, Fricker G. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 2002;110:1309-18.
Kemper E M, Zandbergen V, Cleypool AE, Mos C, Boogerd HA, Beijnen W, Tellingen JHV. Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein. J Clin Cancer Res 2003:9:2849-55.
Colabufo NA, Berardi F, Perrone R, Rapposelli S, Digiacomo M, Balsamo A. Arylmethyloxyphenyl Derivatives:Small Molecules Displaying P-Glycoprotein Inhibition. J Med Chem 2006;49:6607-13.
Gannon MK, Holt JJ, Bennett SM, Wetzel BR, Loot WM, Bartlett C,. Clarke DM, Sawada GA,. Higgins JW, Tombline G, Raub TJ, Detty MR. Rhodamine Inhibitors of P-Glycoprotein:An Amide/Thioamide Switch†for ATPase Activity. J Med chem 2009,52,3328-41.
Robert J, Jarry C. Multidrug Resistance Reversal Agents. J Med Chem 2004;46:1726-29.
Ehrlich P. Ueber den jetzigen Stand der Chemotherapie. J Ber Dtsch Chem Ges 1909;42:17-47.
Dayam R, Sanchez T, Clement O, Shoemaker R, Sei S, Neamati N. β-Diketo Acid Pharmacophore Hypothesis,Discovery of a Novel Class of HIV-1 Integrase Inhibitors. J Med Chem 2005;48:111-20.
Gundla R, Kazemi R, Sanam R, Muttineni R, Sarma A R P, Dayam R, Neamati N. Discovery of Novel Small-Molecule Inhibitors of Human Epidermal Growth Factor Receptor-2:Combined Ligand and Target-Based Approach. J Med Chem 2008;51:3367-77.
Elhallaoui M, •Laguerre M, Carpy A, Ouazzani FC. Molecular modeling of noncompetitive antagonistsof the NMDA receptor proposal of a pharmacophoreand a description of the interaction mode. J Mol Model 2002;8:65-72.
Hong H, Neamati N, Wang W, Nicklaus MC, Mazumder M, Zhao H, et al. Milne WA. Discovery of HIV-1 Integrase Inhibitors by Pharmacophore Searching. J Med Chem 1997;40:1123-8.
Pickett SD, Mason JS, McLay IM. Diversity Profiling and Design Using 3D Pharmacophores:Pharmacophore-Derived Queries. J Chem Inf Comput Sci 1996;36:1214-23.
Sharma MC. Molecular modeling and pharmacophore approach substituted benzimidazole derivatives as dipeptidyl peptidase IV inhibitors. J of Saudi Chemical Society 2013.
Brogia S, Papazafiri P, Roussis V, Tafi A. 3D-QSAR using pharmacophore-based alignment and virtual screening for discovery of novel MCF-7 cell line inhibitors. Eur J Med Chem 2013;67:344-51.
Vyas VK, Ghate M, Goel A. Pharmacophore modeling, virtual screening, docking and in silico ADME analysis of protein kinase B (PKB) inhibitors. J Mol Graphics Modell 2013;42:17-25.
Rodrguez ML, Porras E, Morcillo MJ, Benham B, Soto LJ, Lavandera JL, Ramos JA, Olivella M, Campillo M, Pardo L. Optimization of the Pharmacophore Model for 5-HT7R Antagonism. Design and Synthesis of New Naphtholactam and Naphthosultam Derivatives. J Med Chem 2003;46:5638-50.
PHASE, Version 3. Schr dinger LLC NY 2008;0.
Maestro, Version 8. Schrdinger LLC NY 2008;5.
Tawari NR, Bag S, Degani MS. Pharmacophore mapping of a series of pyrrolopyrimidines, indolopyrimidines and their congeners as multidrug-resistance-associated protein (MRP1) modulators. Journal of molecular modeling 2008;14(10):911-21.
Qian F, Wei D, Liu J, Yang S. Molecular Model and ATPase Activity of Carboxyl_Terminal Nucleotide Binding Domain from Human P_Glycoprotein. J Biochemistry (Moscow) 2006;71:S18-S24.
S. Wold, Quant. Struct. Act. Relat. Journal of molecular modeling 1991;10:191-3.
Robert J, Jarry C, Multidrug Resistance Reversal Agents. J Med Chem 2003;46:23.
Amin ML. P-glycoprotein Inhibition for Optimal Drug Delivery. J Drug Target Insights 2013:7 27-34.
Martelli C, Coronnello M, Dei S, Manetti D, Orlandi F, Scapecchi S, et al. Structure-Activity Relationships Studies in a Series of N,N-Bis(alkanol)amine Aryl Esters as P-Med. Chem XXXX XXX:000.
Dureja H, Kumar V, Gupta V, Madan AK. J Theo Comput Chem 2007;6:435-48.